186 related articles for article (PubMed ID: 22566415)
21. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2020.
Pingali C; Yankey D; Elam-Evans LD; Markowitz LE; Williams CL; Fredua B; McNamara LA; Stokley S; Singleton JA
MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(35):1183-1190. PubMed ID: 34473682
[TBL] [Abstract][Full Text] [Related]
22. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2019.
Elam-Evans LD; Yankey D; Singleton JA; Sterrett N; Markowitz LE; Williams CL; Fredua B; McNamara L; Stokley S
MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(33):1109-1116. PubMed ID: 32817598
[TBL] [Abstract][Full Text] [Related]
23. Compliance with recommendations and opportunities for vaccination at ages 11 to 12 years: evaluation of the 2009 national immunization survey-teen.
Stokley S; Cohn A; Jain N; McCauley MM
Arch Pediatr Adolesc Med; 2011 Sep; 165(9):813-8. PubMed ID: 21893647
[TBL] [Abstract][Full Text] [Related]
24. Gender of the Clinician, Child, and Guardian and the Association With Receipt of Routine Adolescent Vaccines.
Faherty LJ; French B; Fiks AG
J Adolesc Health; 2016 Jul; 59(1):116-22. PubMed ID: 27188630
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
John T; Voysey M; Yu LM; McCarthy N; Baudin M; Richard P; Fiquet A; Kitchin N; Pollard AJ
Vaccine; 2015 Aug; 33(36):4579-85. PubMed ID: 26165918
[TBL] [Abstract][Full Text] [Related]
26. Effect on meningococcal serogroup W immunogenicity when Tdap was administered prior, concurrent or subsequent to the quadrivalent (ACWY) meningococcal CRM
Tashani M; Badahdah AM; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Louth J; Rashid H; Borrow R; Booy R
Vaccine; 2019 Jun; 37(27):3562-3567. PubMed ID: 31128875
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
[TBL] [Abstract][Full Text] [Related]
28. Measuring Adolescent Human Papillomavirus Vaccine Coverage: A Match of Sexually Transmitted Disease Clinic and Immunization Registry Data.
Pathela P; Jamison K; Papadouka V; Kabir R; Markowitz LE; Dunne EF; Schillinger JA
J Adolesc Health; 2016 Dec; 59(6):710-715. PubMed ID: 27671357
[TBL] [Abstract][Full Text] [Related]
29. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2017.
Walker TY; Elam-Evans LD; Yankey D; Markowitz LE; Williams CL; Mbaeyi SA; Fredua B; Stokley S
MMWR Morb Mortal Wkly Rep; 2018 Aug; 67(33):909-917. PubMed ID: 30138305
[TBL] [Abstract][Full Text] [Related]
30. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
31. The Need to Optimize Adolescent Immunization.
Bernstein HH; Bocchini JA;
Pediatrics; 2017 Mar; 139(3):. PubMed ID: 28167517
[TBL] [Abstract][Full Text] [Related]
32. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
33. Using the 4 Pillars™ Practice Transformation Program to increase adolescent human papillomavirus, meningococcal, tetanus-diphtheria-pertussis and influenza vaccination.
Zimmerman RK; Raviotta JM; Nowalk MP; Moehling KK; Reis EC; Humiston SG; Lin CJ
Vaccine; 2017 Oct; 35(45):6180-6186. PubMed ID: 28947346
[TBL] [Abstract][Full Text] [Related]
34. The impact of computer-generated messages on childhood immunization coverage.
Dini EF; Linkins RW; Sigafoos J
Am J Prev Med; 2000 Feb; 18(2):132-9. PubMed ID: 10698243
[TBL] [Abstract][Full Text] [Related]
35. Middle school vaccination requirements and adolescent vaccination coverage.
Bugenske E; Stokley S; Kennedy A; Dorell C
Pediatrics; 2012 Jun; 129(6):1056-63. PubMed ID: 22566425
[TBL] [Abstract][Full Text] [Related]
36. Early Outcomes of a Multilevel Human Papillomavirus Vaccination Pilot Intervention in Federally Qualified Health Centers.
Fisher-Borne M; Preiss AJ; Black M; Roberts K; Saslow D
Acad Pediatr; 2018 Mar; 18(2S):S79-S84. PubMed ID: 29502642
[TBL] [Abstract][Full Text] [Related]
37. Text4Health: impact of text message reminder-recalls for pediatric and adolescent immunizations.
Stockwell MS; Kharbanda EO; Martinez RA; Lara M; Vawdrey D; Natarajan K; Rickert VI
Am J Public Health; 2012 Feb; 102(2):e15-21. PubMed ID: 22390457
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.
Arguedas A; Soley C; Loaiza C; Rincon G; Guevara S; Perez A; Porras W; Alvarado O; Aguilar L; Abdelnour A; Grunwald U; Bedell L; Anemona A; Dull PM
Vaccine; 2010 Apr; 28(18):3171-9. PubMed ID: 20189491
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial.
Wheeler CM; Harvey BM; Pichichero ME; Simon MW; Combs SP; Blatter MM; Marshall GS; Catteau G; Dobbelaere K; Descamps D; Dubin G; Schuind A
Pediatr Infect Dis J; 2011 Dec; 30(12):e225-34. PubMed ID: 21817954
[TBL] [Abstract][Full Text] [Related]
40. Centralized Reminder/Recall to Increase Immunization Rates in Young Children: How Much Bang for the Buck?
Kempe A; Saville AW; Beaty B; Dickinson LM; Gurfinkel D; Eisert S; Roth H; Herrero D; Trefren L; Herlihy R
Acad Pediatr; 2017 Apr; 17(3):330-338. PubMed ID: 27913163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
